radionuclide angiography

The technique of dynamic hepatic radionuclide angiography has been described previously in detail.

The application of radionuclide angiography in assessing portal vein patency or occlusion has received limited attention.

SnCl is used in Radionuclide angiography to reduce the radioactive agent technetium-99m-pertechnetate to assist in binding to blood cells.

The present investigation is the first report of radionuclide angiography specifically used to assess the patency/occlusion of the portal venous system.

Several investigators have attempted to define the portal venous and hepatic arterial contributions to total liver blood flow by non-invasive means including ultrasound and radionuclide angiography.

Nevertheless, at a % PV flow of below 20%, radionuclide angiography allowed a clear distinction to be made between patients with a patient and obstructed portal venous system.

Further evauation of radionuclide angiography in comparison with other non-invasive methods (ultrasound, computer tomography, and nuclear magnetic resonance) and conventional arterial portography merits consideration.

Non-invasive radionuclide angiography provides a safe and accurate screening method for evaluating portal vein patence on occlusion in the investigation of portal hypertension or before liver transplantation.

It is also called radionuclide angiography, radionuclide ventriculography, or gated blood pool imaging, as well as SYMA (SYnchronized Multigated Acquisition) scan.

In conclusion, this study shows that non-invasive radionuclide angiography is of benefit in screening for obstruction within the portal vein as part of the preliminary investigation of portal hypertension and chronic liver disease or during the assessment for liver transplantation.